Tempus ai tem stock forecast real-time data indicates TEM’s relative

Real-time data indicates TEM’s relative strength index (RSI) at 62, nearing overbought territory. The stock forecast models project steady gains if upcoming product pipeline news hits positive benchmarks before September. These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Tempus AI's past performance and to peers in the same industry. The analysts are definitely expecting Tempus AI's growth to accelerate, with the forecast 69% annualised growth to the end of 2025 ranking favourably alongside historical growth of 31% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 6.0% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Tempus AI to grow faster than the wider industry. This level of growth isn’t unprecedented. Look at Intuitive Surgical , which jumped 8x in value over the past decade—from $20 billion to $165 billion. The best part? We don’t think ISRG stock is done yet . Tempus AI may follow a similar trajectory. AI healthcare adoption rates reported by industry trackers hit 18% YoY growth, underpinning TEM stock forecasts. Analysts project an earnings surprise factor of 1.2x versus prior guidance, sustaining investor optimism.